Kadimastem (XTAE:KDST) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:KDST Kadimastem Ltd XTAE:KDST
21 GF Score
Price ₪39.58
! 4 Warning Signs
View Full Analysis

What is Kadimastem Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XTAE:KDST vs MRKR, HOWL, CVM: Short Percentage of Float Comparison

For the Biotechnology subindustry, Kadimastem's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kadimastem Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kadimastem's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Kadimastem's Short Percentage of Float falls into.


XTAE:KDST
21GF Score
Kadimastem Ltd XTAE:KDST
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kadimastem Business Description

Other Exchanges NCEL:USA
Address Hohstrasse 1, Kloten, CHE, 8302
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
21GF Score

Get the complete analysis for XTAE:KDST

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪39.58
Price